lithium carbonate - Medications

Lithium Carbonate Extended-Release Tablets, USP contain lithium carbonate, USP a white, light alkaline powder with molecular formula Li 2 CO 3 and molecular weight 73.89. Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94 and an emission line at 671 nm on the flame photometer. The tablets meet the requirements of USP Dissolution Test 2 in the USP monograph for Lithium Carbonate Extended-release Tablets, USP. Lithium Carbonate Extended-Release Tablets: Each speckled, off-white to yellow, round biconvex tablet, debossed with “54 346” on one side and scored on the other side, contains lithium carbonate, 450 mg. Inactive ingredients consist of iron oxide (yellow), magnesium stearate, povidone, sodium alginate and sodium starch glycolate. Lithium Carbonate Extended-Release Tablets USP, 450 mg are designed to release a portion of the dose initially and the remainder gradually; the release pattern of the controlled release tablets reduces the variability in lithium blood levels seen with the immediate release dosage forms.

Lithium Carbonate Extended-Release Tablets USP contain lithium carbonate USP, a white, light alkaline powder with molecular formula Li 2 CO 3 and molecular weight 73.89. Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94 and an emission line at 671 nm on the flame photometer. The tablets meet the requirements of USP Dissolution Test 2 in the USP monograph for Lithium Carbonate Extended-release Tablets, USP. Lithium Carbonate Extended-Release Tablets: Each speckled, off-white to yellow, round biconvex tablet, debossed with “54 346” on one side and scored on the other side, contains lithium carbonate, 450 mg. Inactive ingredients consist of iron oxide (yellow), magnesium stearate, povidone, sodium alginate and sodium starch glycolate. Lithium Carbonate Extended-Release Tablets USP, 450 mg are designed to release a portion of the dose initially and the remainder gradually; the release pattern of the controlled release tablets reduces the variability in lithium blood levels seen with the immediate release dosage forms.

Each tablet for oral administration contains lithium carbonate USP, 300 mg and the following inactive ingredients: calcium stearate, microcrystalline cellulose, povidone, purified water, sodium lauryl sulfate, and sodium starch glycolate. Each capsule for oral administration contains lithium carbonate USP, 150 mg, 300 mg or 600 mg and the following inactive ingredient: talc. The capsule shells contain black monogramming ink, FD&C Red No. 40 (300 mg and 600 mg only), gelatin and titanium dioxide. The black monogramming ink contains ammonium hydroxide, ethanol, iron oxide black, isopropyl alcohol, N-butyl alcohol, propylene glycol and shellac glaze. Each 5 mL of solution for oral administration contains lithium ion (Li+), 8 mEq (equivalent to amount of lithium in 300 mg of lithium carbonate), alcohol 0.3% v/v and the following other inactive ingredients: citric acid, purified water, raspberry blend, sodium benzoate and sorbitol solution. Lithium Oral Solution is a palatable oral dosage form of lithium ion. It is prepared in solution from lithium hydroxide and citric acid in a ratio approximately di-lithium citrate. Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94, and an emission line at 671 nm on the flame photometer. The empirical formula for Lithium Citrate is C 6 H 5 Li 3 O 7 ; molecular weight 209.93. Lithium acts as an antimanic. Lithium Carbonate USP is a granular, white powder with molecular formula Li 2 CO 3 and molecular weight 73.89.

Lithium carbonate extended-release tablets USP contain lithium carbonate, a white odorless alkaline powder with molecular formula Li 2 CO 3 and molecular weight 73.89. Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94, and an emission line at 671 nm on the flame photometer. Each peach-colored, round biconvex film-coated, extended-release tablet contains 300 mg of lithium carbonate. This slowly dissolving film-coated tablet is designed to give lower serum lithium peak concentrations than obtained with conventional oral lithium dosage forms. Inactive ingredients consist of black ink S-1-277001 (contains Black Iron Oxide, Propylene Glycol, Shellac Glaze (Modified) IN SD-45), calcium stearate, hypromellose, opadry pink (carnauba wax, FD&C Blue No. 2 Aluminium Lake, FD&C Red No. 40 Aluminium Lake, FD&C Yellow No. 6 Aluminium Lake, hypromellose, polyethylene glycol, propylene glycol, titanium dioxide), povidone and sodium lauryl sulfate.

Each capsule for oral administration contains lithium carbonate, USP 150 mg, 300 mg or 600 mg and the following inactive ingredients: colloidal silicon dioxide, gelatin, sodium lauryl sulfate, talc, titanium dioxide, FD&C Blue No. 1, FD&C Red No. 40, D&C Yellow No. 10, and the imprinting ink contains shellac, propylene glycol, potassium hydroxide, and black iron oxide. Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94, and an emission line at 671 nm on the flame photometer. Lithium Carbonate, USP is a white, crystalline powder with molecular formula Li 2 CO 3 and molecular weight 73.89.

Each capsule for oral administration contains lithium carbonate USP, 150 mg, 300 mg or 600 mg and the following inactive ingredients: colloidal silicon dioxide, gelatin, sodium lauryl sulfate, talc, titanium dioxide, FD&C Blue No. 1, FD&C Red No. 40, D&C Yellow No. 10, and the imprinting ink contains shellac, propylene glycol, potassium hydroxide, and black iron oxide. Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94, and an emission line at 671 nm on the flame photometer. Lithium Carbonate USP is a white, crystalline powder with molecular formula Li 2 CO 3 and molecular weight 73.89 g/mol.

Each tablet for oral administration contains lithium carbonate USP, 300 mg and the following inactive ingredients: calcium stearate, microcrystalline cellulose, povidone, purified water, sodium lauryl sulfate, and sodium starch glycolate. Each capsule for oral administration contains lithium carbonate USP, 150 mg, 300 mg or 600 mg and the following inactive ingredient: talc. The capsule shells contain black monogramming ink, FD&C Red No. 40 (300 mg and 600 mg only), gelatin and titanium dioxide. The black monogramming ink contains ammonium hydroxide, ethanol, iron oxide black, isopropyl alcohol, N-butyl alcohol, propylene glycol and shellac glaze. Each 5 mL of solution for oral administration contains lithium ion (Li+), 8 mEq (equivalent to amount of lithium in 300 mg of lithium carbonate), alcohol 0.3% v/v and the following other inactive ingredients: citric acid, purified water, raspberry blend, sodium benzoate and sorbitol solution. Lithium Oral Solution is a palatable oral dosage form of lithium ion. It is prepared in solution from lithium hydroxide and citric acid in a ratio approximately di-lithium citrate. Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94, and an emission line at 671 nm on the flame photometer. The empirical formula for Lithium Citrate is C 6 H 5 Li 3 O 7 ; molecular weight 209.93. Lithium acts as an antimanic. Lithium Carbonate USP is a granular, white powder with molecular formula Li 2 CO 3 and molecular weight 73.89.

Lithium Carbonate Extended-release Tablets, USP contain lithium carbonate, USP, a white granular powder with molecular formula Li 2 CO 3 and molecular weight 73.89. Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94 and an emission line at 671 nm on the flame photometer. Lithium Carbonate Extended-release Tablets USP are available for oral administration containing 300 mg of lithium carbonate USP. This slowly dissolving, film-coated tablet is designed to give lower serum lithium peak concentrations than obtained with conventional oral lithium dosage forms. Each tablet contains the following inactive ingredients: calcium stearate, Opadry II (Beige), povidone, sodium chloride, sodium lauryl sulfate, and sorbitol. Opadry II (Beige) contains: hypromellose, polydextrose, polyethylene glycol, red iron oxide, titanium dioxide, triacetin, and yellow iron oxide. The tablets meet the requirements of USP Dissolution Test 5 in the USP monograph for Lithium Carbonate Extended-release Tablets USP, 300 mg.

Lithium carbonate extended-release tablets, USP contain lithium carbonate, a white crystalline powder with molecular formula Li 2 CO 3 and molecular weight 73.89. Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94, and an emission line at 671 nm on the flame photometer. Each peach-colored, film-coated, extended-release tablet contains 300 mg of lithium carbonate. This slowly dissolving film-coated tablet is designed to give lower serum lithium peak concentrations than obtained with conventional oral lithium dosage forms. Inactive ingredients consist of calcium stearate, carnauba wax, povidone, sodium chloride, sodium lauryl sulfate, sodium starch glycolate, sorbitol, propylene glycol, hypromellose, FD&C Blue No. 2 Aluminum Lake, FD&C Red No. 40 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake, and titanium dioxide. Product meets USP Drug Release Test 1.

Lithium carbonate extended-release tablets, USP contain lithium carbonate, USP, a white, granular, odorless powder with molecular formula Li 2 CO 3 and molecular weight 73.89. Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94, and an emission line at 671 nm on the flame photometer. Each peach, film-coated, extended-release tablet contains 300 mg of lithium carbonate. This slowly dissolving film-coated tablet is designed to give lower serum lithium peak concentrations than obtained with conventional oral lithium dosage forms. Inactive ingredients consist of calcium stearate, hypromellose, polydextrose, povidone, polyethylene glycol, red iron oxide, sodium chloride, sodium lauryl sulfate, sorbitol, titanium dioxide, triacetin, and yellow iron oxide. Meets USP Dissolution Test 4.

Lithium Carbonate Extended-Release Tablets, USP contain lithium carbonate, USP a white crystalline powder with molecular formula Li 2 CO 3 and molecular weight 73.89. Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94, and an emission line at 671 nm on the flame photometer. Each light pink to pink colored circular, biconvex, coated, extended-release tablet contains 300 mg of lithium carbonate, USP. This slowly dissolving film-coated tablet is designed to give lower serum lithium peak concentrations than obtained with conventional oral lithium dosage forms. Inactive ingredients consist of sodium chloride, povidone, sorbitol, sodium starch glycolate, sodium lauryl sulfate, calcium stearate, hypromellose, titanium dioxide, polyethylene glycol and iron oxide red. Product meets USP Dissolution Test 1.

Lithium Carbonate Extended-release Tablets, USP contain lithium carbonate, USP, a white granular powder with molecular formula Li 2 CO 3 and molecular weight 73.89. Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94 and an emission line at 671 nm on the flame photometer. Lithium Carbonate Extended-release Tablets, USP are available for oral administration containing 300 mg of lithium carbonate USP. This slowly dissolving, film-coated tablet is designed to give lower serum lithium peak concentrations than obtained with conventional oral lithium dosage forms. Each tablet contains the following inactive ingredients: calcium stearate, Opadry II (Beige), povidone, sodium chloride, sodium lauryl sulfate and sorbitol. Opadry II (Beige) contains: hypromellose, polydextrose, polyethylene glycol, red iron oxide, titanium dioxide, triacetin and yellow iron oxide. The tablets meet the requirements of USP Dissolution Test 5 in the USP monograph for Lithium Carbonate Extended-release Tablets USP, 300 mg.

Lithium carbonate extended-release tablets contain lithium carbonate, a white odorless alkaline powder with molecular formula Li 2 CO 3 and molecular weight 73.89. Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94, and an emission line at 671 nm on the flame photometer. Each beige-colored, film-coated, extended-release tablet contains 300 mg of lithium carbonate. This slowly dissolving film-coated tablet is designed to give lower serum lithium peak concentrations than obtained with conventional oral lithium dosage forms. Inactive ingredients consist of calcium stearate, FD&C Blue No. 2 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake, hypromellose, polydextrose, polyethylene glycol, povidone, sodium chloride, sodium lauryl sulfate, sodium starch glycolate, sorbitol, titanium dioxide and triacetin. Meets USP Dissolution Test 4.

Lithium Carbonate Extended-Release Tablets USP, contain lithium carbonate USP, a white, crystalline powder with molecular formula Li 2 CO 3 and molecular weight 73.89 g/mol. Lithium is an element of the alkali‑metal group with atomic number 3, atomic weight 6.94 and an emission line at 671 nm on the flame photometer. Lithium Carbonate Extended-Release Tablets USP Each off-white to pale yellow, circular, beveled edged, biconvex uncoated tablets with ‘224’ debossed on one side, ‘G’ and a break line debossed on the other side, contains lithium carbonate, 450 mg. Inactive ingredients consist of ferric oxide yellow, hypromellose, magnesium stearate, microcrystalline cellulose, sodium alginate, sodium starch glycolate and talc. Product meets USP Dissolution Test 2. Lithium Carbonate Extended-Release Tablets USP, 450 mg are designed to release a portion of the dose initially and the remainder gradually; the release pattern of the controlled release tablets reduces the variability in lithium blood levels seen with the immediate release dosage forms.

Lithium Carbonate Extended-Release Tablets USP, contain lithium carbonate USP, a white, crystalline powder with molecular formula Li 2 CO 3 and molecular weight 73.89 g/mol. Lithium is an element of the alkali‑metal group with atomic number 3, atomic weight 6.94 and an emission line at 671 nm on the flame photometer. Lithium Carbonate Extended-Release Tablets USP Each off-white to pale yellow, circular, beveled edged, biconvex uncoated tablets with ‘224’ debossed on one side, ‘G’ and a break line debossed on the other side, contains lithium carbonate, 450 mg. Inactive ingredients consist of ferric oxide yellow, hypromellose, magnesium stearate, microcrystalline cellulose, sodium alginate, sodium starch glycolate and talc. Product meets USP Dissolution Test 2. Lithium Carbonate Extended-Release Tablets USP, 450 mg are designed to release a portion of the dose initially and the remainder gradually; the release pattern of the controlled release tablets reduces the variability in lithium blood levels seen with the immediate release dosage forms.

Each capsule for oral administration contains lithium carbonate USP, 150 mg, 300 mg, or 600 mg and the following inactive ingredients: talc, gelatin, FD&C Red No. 40, titanium dioxide, D&C Yellow No. 10, FD&C Yellow No. 6, and the imprinting ink contains black iron oxide, & Pharmaceutical glaze. Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94, and an emission line at 671 nm on the flame photometer. Lithium Carbonate, USP is a granular, white powder with molecular formula Li 2 CO 3 and molecular weight 73.89.

Joint pains*

Summary not available yet.

Joint pains*

LITHOBID ® tablets contain lithium carbonate, a white odorless alkaline powder with molecular formula Li 2 CO 3 and molecular weight 73.89. Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94, and an emission line at 671 nm on the flame photometer. Each peach-colored, film-coated, extended-release tablet contains 300 mg of lithium carbonate. This slowly dissolving film-coated tablet is designed to give lower serum lithium peak concentrations than obtained with conventional oral lithium dosage forms. Inactive ingredients consist of calcium stearate, carnauba wax, cellulose compounds, FD&C Blue No. 2 Aluminum Lake, FD&C Red No. 40 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake, povidone, propylene glycol, sodium chloride, sodium lauryl sulfate, sodium starch glycolate, sorbitol, and titanium dioxide. Product meets USP Drug Release Test 1.

INDICATIONS For the temporary relief of sadness, anxiousness, difficulty concentrating, or fatigue.*

USES: For temporary relief of imbalances in menstruation and ovulation, insomnia, dysmenorrhea and imbalance in menstrual cycle.** **Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.

INDICATIONS: For temporary relief of exhaustion, vomiting, prostration, and metallic taste.

INDICATIONS: May temporarily relieve vomiting, exhaustion, and metallic taste.** **Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.

INDICATIONS: For temporary relief of symptoms related to heavy metal toxicity including cough, poor concentration, nausea, vomiting, occasional diarrhea, stomach pain, headache, sweating, and a metallic taste in the mouth.** **These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.

USES: • For the temporary relief of symptoms including: • symptoms of heavy metal toxicity • stomach inflammation • cough • poor concentration • nausea • vomiting • occasional diarrhea • stomach pain • headache • sweating • metallic taste These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.

USES: • For the temporary relief of symptoms including: • symptoms of heavy metal toxicity • stomach inflammation • cough • poor concentration • nausea • vomiting • occasional diarrhea • stomach pain • headache • sweating • metallic taste These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.

INDICATIONS: Aids in mood balance.† †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.

HOMEOPATHIC INDICATIONS: For temporary relief of symptoms related to Mood swings such as loss of interest, guilt, grandiose ego, racing thoughts, hyperactivity, impulsiveness and inattention.** **These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.

USES: • For the temporary relief of symptoms including: • mood swings • loss of interest • guilt • grandiosity • racing thoughts • excess energy • impulsiveness • inattention These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.

USES: • For the temporary relief of symptoms including: • lack of motivation • boredom • loathing of work • averse mental work • loss of ambition • mental fatigue • lack of confidence • hopelessness • lack of passion These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.

INDICATIONS Temporary relief of symptoms associated with mental fatigue, such as: lapses in ability to remember facts, names or words; and feelings of confusion or difficulty in collecting one's thoughts. Increases cerebral vascularisation.

Uses* According to homeopathic indications these ingredients provide temporary relief from symptoms such as: Joint Pain Stiffness Swelling Immobility. *These statements are based upon traditional homeopathic practice. They have not been reviewed by the Food and Drug Administration.

Uses For temporary relief of occasional: Minor aches and pains Stiffness of muscles, joints, and tissues Indications are based on homeopathic materia medica, not clinical tests.

INDICATIONS: For temporary relief of symptoms due to numbness, tingling, muscle cramps, and nerve pain.

INDICATIONS: For temporary relief of symptoms due to numbness, tingling, muscle cramps, and nerve pain.

INDICATIONS: For temporary relief of symptoms due to numbness, tingling, muscle cramps, and nerve pain.

USES: • For the temporary relief of symptoms including: • pain under arm • back pain • irritability • fever • headache • general pain • hearing loss • sweat • coldness These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.

HOMEOPATHIC INDICATIONS: For the temporary relief of symptoms of stress such as terror, horror, post traumatic stress, fight or flight response, recurring nightmares, difficulty sleeping, difficulty concentrating, restlessness, and easy irritability.** **These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.

USES: • For the temporary relief of symptoms including: • terror • horror • stress • fight or flight • nightmares • difficulty sleeping • easy irritability • difficulty concentrating • restlessness These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.

USES: • For the temporary relief of symptoms including: • terror • horror • stress • fight or flight • nightmares • difficulty sleeping • easy irritability • difficulty concentrating • restlessness These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.

Uses Temporary relief of urinary discomfort, skin rashes.

INDICATIONS For the temporary relief of minor nausea or vomiting, mild abdominal pain, changes in appetite, fatigue, disturbed sleep, or muscle cramps.*

INDICATIONS: Provides specific sarcode support for the kidneys.† †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.

INDICATIONS: May temporarily relieve pain in the abdomen extending around to the back, pain in the thighs and loins on urinating and frequent urination.** **Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.

INDICATIONS: For temporary relief of pain in the abdomen extending around to the back, pain in the thighs and loins on urinating and frequent urination.

INDICATIONS: For temporary relief of pain in the abdomen extending around to the back, pain in the thighs and loins on urinating and frequent urination.

INDICATIONS: For temporary relief of pain in the abdomen extending around to the back, pain in the thighs and loins on urinating and frequent urination.

INDICATIONS & USAGE SECTION Formulated for associated symptoms such as inflammatoin, sharp or throbbing pain, numbness and backache.

INDICATIONS & USAGE SECTION Formulated for associated symptoms such as sharp or throbbing pain, Inflammation, numbness and discomfort.